Plain-English translation of NCT06831071 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This study is testing whether a medication called can help doctors better understand early-stage melanoma. Researchers believe that tumors with low oxygen levels may behave differently and spread more aggressively, and they want to see if measuring oxygen in your tumor and nearby lymph nodes could help predict how your cancer might progress.
Previous research found that low oxygen levels inside advanced melanomas were linked to worse outcomes. This trial wants to know if the same is true for earlier-stage melanomas, which could eventually help doctors predict which patients need closer monitoring or more aggressive treatment.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of , a medication that helps mark areas with low oxygen in your tumor. The medication is given before your scheduled sentinel lymph node biopsy (the surgery your doctor already planned). Researchers will then examine your tumor and lymph node samples under a microscope to measure oxygen levels and see if there is a connection to how your cancer might progress.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
Yana Najjar
Collaborators
Hypoxyprobe
Enrollment target
~50 participants
Started
April 2025
Primary completion
March 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Danielle L Bednarz, RN, BSN
UPMC Hillman Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.